Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study

Overview

Journal Eur J Breast Health

Publisher Galenos Publishing House

Date 2021 Apr 19

PMID 33870115

Citations 8

Authors

Gary Donovitz

Mandy Cotten

Affiliations

Soon will be listed here.

Abstract

Objective: Testosterone (T) therapy has been shown to be breast protective in both pre- and post-menopausal patients. Additionally, estradiol (E) does not cause breast cancer (BC) in the majority of the world's literatures. This study aimed to investigate the incidence of invasive BC (IBC) in pre- and postmenopausal women treated with T therapy and T in combination with E (T/E).

Materials And Methods: Since January 2010, a total of 2,377 pre- and post-menopausal women were treated with T or T/E implants. IBC rates were reported based on newly diagnosed IBC cases in the total study. Total cases divided by the total sample size and years in study was expressed as an incidence per 100,000 person-years (P-Ys). The BC incidence was compared with age-specific Surveillance Epidemiology and End Results (SEER) incidence rates.

Results: As of October 2020, 14 cases diagnosed with IBC have been found in 9,746 P-Y of follow up for an incidence of 144 cases per 100,000 P-Y, substantially less than the age-specific SEER incidence rates (223/100,000), placebo arm of Women's Health Initiative Study (330/100,000), and never users of hormone therapy from the Million Women Study (312/100,000).

Conclusion: T and/or T/E pellet implants significantly reduced the incidence of BC in pre- and post-menopausal women. The addition of E did not increase the incidence over using T alone. This is the second multi-year long-term study demonstrating the benefits of T therapy in reducing the incidence of IBC.

Citing Articles

Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women.

Renke G, Antunes M, Sakata R, Tostes F Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338410 PMC: 11434735. DOI: 10.3390/ph17091248.

Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.

Heng Y, Baker G, Fein-Zachary V, Guzman-Arocho Y, Bret-Mounet V, Massicott E Breast Cancer Res. 2024; 26(1):109.

PMID: 38956693 PMC: 11221014. DOI: 10.1186/s13058-024-01867-w.

A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic Target.

Fernandez-Murga M, Gil-Ortiz F, Serrano-Garcia L, Llombart-Cussac A Pathogens. 2023; 12(9).

PMID: 37764894 PMC: 10535898. DOI: 10.3390/pathogens12091086.

Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?.

Renke G, Tostes F Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111376 PMC: 10146246. DOI: 10.3390/ph16040619.

Sex hormones in the risk of breast cancer: a two-sample Mendelian randomization study.

Ke B, Li C, Shang H Am J Cancer Res. 2023; 13(3):1128-1136.

PMID: 37034223 PMC: 10077051.

References

Hofling M, Linden Hirschberg A, Skoog L, Tani E, Hagerstrom T, von Schoultz B . Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause. 2006; 14(2):183-90. DOI: 10.1097/01.gme.0000232033.92411.51. View

. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159-1168. PMC: 6891893. DOI: 10.1016/S0140-6736(19)31709-X. View

Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M . Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010; 56(16):1310-6. DOI: 10.1016/j.jacc.2010.03.090. View

Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P . Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep. 1981; 65(3-4):179-85. View

Lambrinoudaki I . Menopausal hormone therapy and breast cancer risk: All progestogens are not the same. Case Rep Womens Health. 2020; 29:e00270. PMC: 7683312. DOI: 10.1016/j.crwh.2020.e00270. View

Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L . Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002; 77(4):660-5. DOI: 10.1016/s0015-0282(02)02969-2. View

Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno M . Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002; 193(1-2):121-8. DOI: 10.1016/s0303-7207(02)00105-3. View

Glaser R, York A, Dimitrakakis C . Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer. 2020; 19(1):1271. PMC: 6937705. DOI: 10.1186/s12885-019-6457-8. View

Colditz G, Hankinson S, Hunter D, Willett W, Manson J, Stampfer M . The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332(24):1589-93. DOI: 10.1056/NEJM199506153322401. View

10.

Traish A, Feeley R, Guay A . Testosterone therapy in women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008. J Sex Med. 2009; 6(2):334-51. DOI: 10.1111/j.1743-6109.2008.01121.x. View

11.

Singhal H, Greene M, Tarulli G, Zarnke A, Bourgo R, Laine M . Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv. 2016; 2(6):e1501924. PMC: 4928895. DOI: 10.1126/sciadv.1501924. View

12.

GREENBLATT R, SURAN R . Indications for hormonal pellets in the therapy of endocrine and gynecic disorders. Am J Obstet Gynecol. 1949; 57(2):294-301. DOI: 10.1016/0002-9378(49)90429-9. View

13.

Manson J, Aragaki A, Rossouw J, Anderson G, Prentice R, LaCroix A . Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017; 318(10):927-938. PMC: 5728370. DOI: 10.1001/jama.2017.11217. View

14.

Dimitrakakis C . Androgens and breast cancer in men and women. Endocrinol Metab Clin North Am. 2011; 40(3):533-47, viii. DOI: 10.1016/j.ecl.2011.05.007. View

15.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

16.

Henderson B, Feigelson H . Hormonal carcinogenesis. Carcinogenesis. 2000; 21(3):427-33. DOI: 10.1093/carcin/21.3.427. View

17.

Studd J, Savvas M, Waston N, Garnett T, Fogelman I, Cooper D . The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol. 1990; 163(5 Pt 1):1474-9. DOI: 10.1016/0002-9378(90)90608-a. View

18.

Franceschini G, Lello S, Di Leone A, Orlandi A, Masetti R . Menopausal hormone therapy: What should be kept in mind for a personalized choice in a shared decision-making. Eur J Obstet Gynecol Reprod Biol. 2019; 246:191-192. DOI: 10.1016/j.ejogrb.2019.12.004. View

19.

Glaser R, York A, Dimitrakakis C . Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas. 2010; 68(4):355-61. DOI: 10.1016/j.maturitas.2010.12.001. View

20.

Glaser R, Kalantaridou S, Dimitrakakis C . Testosterone implants in women: pharmacological dosing for a physiologic effect. Maturitas. 2012; 74(2):179-84. DOI: 10.1016/j.maturitas.2012.11.004. View